Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening

Keith V Nance
Medical Directory of Cytology, Rex Hospital, Raleigh, and Department of Pathology, The University of North Carolina School of Medicine, Chapel Hill, NC, USA

Dear editor
I read with interest the recently published article by Naryshkin and Austin entitled “Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening”.

The article is a single case report of squamous cell carcinoma of the cervix diagnosed in a patient who had negative Hybrid Capture 2 (Qiagen NV, Hilden, Germany) high-risk human papillomavirus testing from SurePath™ (Becton-Dickinson, Franklin Lakes, NJ) samples. The authors then discuss several valid points regarding the use of human papillomavirus testing and cervical cancer screening not approved by the US Food and Drug Administration (FDA). Their conclusion is that such testing should not be done using the SurePath collection medium.

Of equal interest is that the article mentions that in Dr Austin’s own laboratory, three of 31 (10%) patients diagnosed with invasive cervical carcinoma and tested within 12 months for high-risk human papillomavirus by Hybrid Capture 2 from FDA-approved Preservcyt® (ThinPrep®) vials also had negative Hybrid Capture 2 results. All three of these patients subsequently had human papillomavirus 18 and/or 16 detected by polymerase chain reaction in paraffin sections of the carcinoma. Should there not have been elaboration on this point with further discussion and perhaps caution regarding use of Hybrid Capture 2 testing using liquid-based cytology specimens of any type, regardless of FDA approval?

Disclosure
The author reports no conflict of interest in this work.

Reference
from the SurePath vial, we were informed that these results were “medically legally sensitive and confidential”.

Given the currently available data and recommendations of one manufacturer and professional organization guidelines, advice to co-collect high-risk HPV test samples in an FDA-approved vial when using SurePath screening appears to represent a conservative patient safety practice. We are also aware of at least one case where a false-negative Hybrid Capture 2 HPV test result obtained on a SurePath vial collected 5 years before a diagnosis of an HPV16-positive advanced-stage cervical cancer appears to have contributed to a delayed cervical cancer diagnosis and a fatal outcome.11

Our case report in Drug Healthcare and Patient Safety further reviews a number of other worrisome “red flags” associated with HPV testing from the formaldehyde-containing SurePath vial,13 still not FDA-approved for HPV testing by any method after over a decade of unsuccessful premarket approval trials. These include issues we have mentioned in several other published articles exploring the limitations of FDA-approved cervical screening test methods.8,14,15 Most recently, we have again specifically called for a targeted nationwide data collection effort to document better the likelihood of false-negative high-risk HPV test results by all HPV test methods over the 5–10 years preceding histopathologic cervical cancer diagnoses.15 We formally made this proposal back in 2011 at the College of American Pathologists and Centers for Disease Control and Prevention-sponsored GYN Practices Consensus Conference, but the meeting leaders elected to refer the proposal for “further study”. Patients have high and sometimes even unrealistic expectations for cervical screening outcomes.16 When clinicians and patients are asked to rely on HPV LDT, they should be informed of alternative recommended FDA-validated methods. Laboratory validation data should be publicly available.

Disclosure
The authors report no conflicts of interest in this work.

References


